Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rocket Pharmaceuticals Inc RCKT

Healthcare Biotechnology
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic... see more

Recent & Breaking News (NDAQ:RCKT)

Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index

Business Wire December 21, 2018

Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Business Wire November 30, 2018

RTW Investments Announces Private Placement Transaction with Rocket Pharmaceuticals, Inc.

Business Wire November 28, 2018

Rocket Pharmaceuticals Prices Public Offering of Common Stock

Business Wire November 27, 2018

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia

Business Wire November 27, 2018

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire November 26, 2018

Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

Business Wire November 26, 2018

Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome

Business Wire November 26, 2018

REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

PR Newswire November 26, 2018

Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program

Business Wire November 25, 2018

Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I)

Business Wire November 19, 2018

Rocket Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

Business Wire November 7, 2018

Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia

Business Wire November 7, 2018

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Business Wire November 1, 2018

Civilization Ventures Achieves Major Win With NASDAQ Listing of Rocket Pharmaceuticals

Business Wire October 29, 2018

Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

Business Wire October 19, 2018

Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

Business Wire October 18, 2018

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Business Wire September 25, 2018

Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Business Wire August 30, 2018

Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

Business Wire August 8, 2018